{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:16:37Z","timestamp":1788264997148,"version":"build-2803163510"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Astra Zeneca"},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate differences in presentation and outcome of GCA patients with and without large vessel vasculitis (LVV) and according to the extent and severity of LVV.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Consecutive patients diagnosed with GCA between 2003 and 2020 who have had FDG PET imaging at diagnosis \u22643\u2009days after initiation of glucocorticoids (GC) and followed for \u226512\u2009months at the University Hospitals Leuven (Belgium) were included retrospectively. PET scans were visually scored (0\u20133) in seven vascular areas and a total vascular score (TVS) was calculated. LVV was defined as FDG uptake \u22652 in any large vessel.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 238 GCA patients, of which 169 (71%) had LVV. LVV patients were younger (69 vs 74\u2009years, P &amp;lt; 0.001) and more frequently female (72% vs 49%, P = 0.001). In patients without PMR symptoms, the presence of LVV was associated with relapse (aOR 3.05 [95% CI 1.32\u20137.43], P = 0.011) and with a lower probability of stopping GC (aHR 0.59 [95% CI 0.37\u20130.94], P = 0.025). However, in those with PMR symptoms, there was no difference in relapse risk (aOR 1.20 [95% CI 0.53\u20132.66], P = 0.657) and in the probability of stopping GC (aHR 1.25 [95% CI 0.75\u20132.09], P = 0.394) between patients with and without LVV. A higher TVS was associated with an increased risk of relapse (aOR 1.09 [95% CI 1.04\u20131.15], P = 0.001) in patients without PMR symptoms, but not in those with PMR symptoms (aOR 1.01 [95% CI 0.96\u20131.07], P = 0.693).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>LVV is a risk factor for relapse in GCA patients without PMR symptoms with a higher relapse risk in those with higher TVS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae456","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T16:43:50Z","timestamp":1724172230000},"page":"2068-2076","source":"Crossref","is-referenced-by-count":3,"title":["Large vessel vasculitis is a risk factor for relapse only in giant cell arteritis patients without polymyalgia rheumatica"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7613-4801","authenticated-orcid":false,"given":"Lien","family":"Moreel","sequence":"first","affiliation":[{"name":"Department of General Internal Medicine, UZ Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Microbiology, Immunology, and Transplantation, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7526-5001","authenticated-orcid":false,"given":"Albrecht","family":"Betrains","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, UZ Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Microbiology, Immunology, and Transplantation, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennert","family":"Boeckxstaens","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, UZ Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Molenberghs","sequence":"additional","affiliation":[{"name":"Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), KU Leuven and Hasselt University , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van Laere","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, UZ Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-2146","authenticated-orcid":false,"given":"Ellen","family":"De Langhe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, UZ Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Development and Regeneration, KU Leuven , Leuven,","place":["Belgium"]},{"name":"European Reference Network for Immunodeficiency, Autoinflammatory, Autoimmune and Pediatric Rheumatic Disease (ERN-RITA) , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Vanderschueren","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, UZ Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Microbiology, Immunology, and Transplantation, KU Leuven , Leuven,","place":["Belgium"]},{"name":"European Reference Network for Immunodeficiency, Autoinflammatory, Autoimmune and Pediatric Rheumatic Disease (ERN-RITA) , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9783-1780","authenticated-orcid":false,"given":"Daniel","family":"Blockmans","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, UZ Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Microbiology, Immunology, and Transplantation, KU Leuven , Leuven,","place":["Belgium"]},{"name":"European Reference Network for Immunodeficiency, Autoinflammatory, Autoimmune and Pediatric Rheumatic Disease (ERN-RITA) , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"2025040212114852300_keae456-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025040212114852300_keae456-B2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"372","author":"Salvarani","year":"2008","journal-title":"Lancet"},{"key":"2025040212114852300_keae456-B3","doi-asserted-by":"crossref","first-page":"105494","DOI":"10.1016\/j.jbspin.2022.105494","article-title":"Epidemiology and predictors of relapse in giant cell arteritis: a systematic review and meta-analysis","volume":"90","author":"Moreel","year":"2023","journal-title":"Jt Bone Spine"},{"key":"2025040212114852300_keae456-B4","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/jcm11041034","article-title":"Impact of glucocorticoid cumulative doses in a real-life cohort of patients affected by giant cell arteritis","volume":"11","author":"Castan","year":"2022","journal-title":"J Clin Med"},{"key":"2025040212114852300_keae456-B5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/BOR.0b013e3282f51031","article-title":"The epidemiology of glucocorticoid-associated adverse events","volume":"20","author":"McDonough","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"2025040212114852300_keae456-B6","first-page":"105706","article-title":"Corrigendum to \u201cEpidemiology and predictors of relapse in giant cell arteritis: a systematic review and meta-analysis\u201d","volume":"91","author":"Moreel","year":"2024","journal-title":"[Joint Bone Spine 2023;90:105494]"},{"key":"2025040212114852300_keae456-B7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/art.21699","article-title":"Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients","volume":"55","author":"Blockmans","year":"2006","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025040212114852300_keae456-B8","first-page":"1908","article-title":"Use of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of polymyalgia rheumatica \u2013 a prospective study of 99 patients","volume":"57","author":"Henckaerts","year":"2018","journal-title":"Rheumatol (United Kingdom)"},{"key":"2025040212114852300_keae456-B9","doi-asserted-by":"crossref","first-page":"105558","DOI":"10.1016\/j.jbspin.2023.105558","article-title":"Clinical phenotype and complications of large vessel giant cell arteritis: a systematic review and meta-analysis","volume":"90","author":"Lyne","year":"2023","journal-title":"Jt Bone Spine"},{"key":"2025040212114852300_keae456-B10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025040212114852300_keae456-B11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/art.40379","article-title":"18F-fluorodeoxyglucose\u2013positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis","volume":"70","author":"Grayson","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025040212114852300_keae456-B12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejim.2022.08.033","article-title":"Persistent FDG uptake in large vessels and risk of relapse in giant cell arteritis","volume":"106","author":"Eshagh","year":"2022","journal-title":"Eur J Intern Med"},{"key":"2025040212114852300_keae456-B13","first-page":"4809","article-title":"The role of PET\/CT in disease activity assessment in patients with large vessel vasculitis","volume":"61","author":"Galli","year":"2022","journal-title":"Rheumatol (United Kingdom)"},{"key":"2025040212114852300_keae456-B14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/1756-185X.13805","article-title":"Cranial and large vessel activity on positron emission tomography scan at diagnosis and 6 months in giant cell arteritis","volume":"23","author":"Sammel","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"2025040212114852300_keae456-B15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejim.2024.03.037","article-title":"Prognostic value of 18 FDG-PET at diagnosis and follow-up in giant cell arteritis: an observational restrospective study","volume":"126","author":"Billet","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2025040212114852300_keae456-B16","first-page":"3710","article-title":"Does the halo count on temporal and axillary ultrasound predict time to relapse in giant cell arteritis?","volume":"62","author":"Esperan\u00e7a Almeida","year":"2023","journal-title":"Rheumatol (United Kingdom)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae456\/58995859\/keae456.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/2068\/58995859\/keae456.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/2068\/58995859\/keae456.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T17:39:22Z","timestamp":1743615562000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/4\/2068\/7738814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8,22]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae456","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,8,22]]}}}